This may help.... To actually effect a reverse split, the

New Post Public Reply Private Reply Replies (0) Message Board

Jun 26, 2012 at 9:15 AM

This may help....

To actually effect a reverse split, the NASDAQ sends to the Company a standard letter, as noted below, covering seven key points :

The instructions below outline the information required by the Corporate Data Operations Department of The NASDAQ OMX Group, Inc. to process a name change, split or merger for an issuer on the OTCBB or Other OTC markets.

A cover letter briefly describing the transaction must be sent to by email from the company or attorney that includes the following details:

Please state the old and new company name. If not applicable please indicate in your correspondence.
Please provide the old as well as the new CUSIP number. You can apply for a new number by contacting the CUSIP Service Bureau at 212-438-6565 or you can apply online at www.cusip.com

Please indicate the effective date NASDAQ OMX should make transaction effective.

Please provide the legal effective date the articles were filed with the Secretary of State or other Registrar.

· Please include a certified stamped copy of the articles/amendments filed.

· If unavailable at the time the document was filed, please forward a copy upon receipt from the Secretary of State or Registrar. Note : NASDAQ OMX cannot process any reorganization for an Other-OTC company without receipt of the certified stamped copy.

· If amendments are not a requirement at the Secretary of State or other Registrar please confirm in your correspondence.

· If a merger please include any terms or consideration given in shares or cash to shareholders.

Please provide a copy of the executed Shareholders Resolution or Inspector of Election Report relating to the corporate action. Please provide an explanation if shareholder approval is not a requirement.
Please provide a copy of the executed Board of Directors Resolution pertaining to the corporate action. If reporting a reverse or forward split please notify NASDAQ OMX 10 calendar days in advance of the record date as noted in SEC Rule 10b-17. If a split is not concurrent with a name change please indicate so in your correspondence.

· Please be advised that the applicable term for a record date is “effective date” for reverse splits and forward splits that are paid upon surrender.

· Please specify the ratio and effective date of the stock split.

· Please indicate the payment method if a forward stock split: payable upon surrender of old certificates or are new shares being mailed direct to shareholder.

· Please note that reverse and forward splits may not have an effective date on bank holidays that the stock market remains open such as Columbus Day and Veterans Day.

Please provide Transfer Agent contact information.

· Name of Agency, contact person, address, phone number, email address

· Please provide the date the transfer agency was appointed as agent.

· If changing transfer agents please provide date of termination of transfer agent.

· Please pass on the attached Transfer Agent Verification Form to your transfer agent. The transfer agent must fill out this form and submit it directly to NASDAQ OMX.

Please remit your request by email to corporateactions@nasdaqomx.com . Once your documentation has been reviewed, the NASDAQ OMX will contact you with any additional inquiries or requests.

Most corporate actions will require a symbol change; such as a change in name, reverse split or forward split paid upon surrender. Unfortunately, symbols may not be reserved for Over the Counter or Over the Counter Bulletin Board markets, nor can the NASDAQ honor requests for specific issue symbols. Additionally, once a symbol is assigned, NASDAQ OMX reserves the 'right' to change the symbol. There can be no guarantee that an OTC issuer will retain their symbol indefinitely.

For questions one should call (203) 375-9609 (NASDAQ OMX Group, Inc.). Their Email Address: corporateactions@nasdaqomx.com and Fax Number: 203-502-5480.

Cotton & Western Mining Inc. (CWRN) Stock Research Links

CWRN Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

LEGO Mashes Star Wars and Marvel for Fans' Delight

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Southern Company Sparks Swift Power Restoration Post-Isaias

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

AI Drives Major Time Savings in Endoscopy Tech

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...